Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation ...

BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech ...

The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...

Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDA’s checkpoint with its PD-L1 inhibitor cosibelimab. The FDA has approved cosibelimab under the brand ...

One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...

Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC: Rahway, New Jersey Wednesday, ...

Source: Getty Images Avelumab plus axitinib did not improve overall survival in the overall population or in patients with PD-L1-positive disease. The median overall survival was 44.8 months in the ...

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in ...

UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...

The following is a summary of “First-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients ...

A year after manufacturing issues resulted in a complete response letter for cosibelimab, the U.S. FDA approved Checkpoint Therapeutics Inc.’s drug, branded Unloxcyt, as the first anti-PD-L1 antibody ...